Progyny narrows FY24 adjusted EPS view to $1.54-$1.57 from $1.53-$1.61

Consensus 71c. Lowers FY24 revenue view to $1.14B-$1.15B from $1.17B-$1.2B, consensus $1.17B. Sees FY24 adjusted EBITDA $189M-$194M. The company said, “As it relates to 2025, consistent with our past practice, we expect to provide financial guidance when we report our year-end results in February, by which time we’ll have insights into our newest clients who are launching on January 1st. Despite the previously-reported loss of a large client, the business remains healthy and we expect to continue generating strong profitability and meaningful cash flow in 2025.”